Why Is Small Cap-Heart Disease Focused Aerovate Therapeutics Stock Plummeting On Monday?
Portfolio Pulse from Vandana Singh
Aerovate Therapeutics Inc (NASDAQ:AVTE) announced that its Phase 2b trial for AV-101, a treatment for pulmonary arterial hypertension, did not meet its primary or secondary endpoints. As a result, the company is halting further trials. The stock plummeted 90.6% on high trading volume.
June 17, 2024 | 1:52 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Aerovate Therapeutics' stock dropped 90.6% after the Phase 2b trial for AV-101 failed to meet its primary and secondary endpoints. The company is halting further trials.
The failure to meet primary and secondary endpoints in a critical Phase 2b trial for AV-101 has led to a significant drop in Aerovate Therapeutics' stock price. The decision to halt further trials exacerbates the negative sentiment.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100